High pulse pressure is a risk factor for prodromal Alzheimer’s disease: a longitudinal study

It has been increasingly evident that pulse pressure (PP) is associated with Alzheimer's disease (AD) but whether PP increases AD risk and the mechanism responsible for this association remains unclear. To investigate the effects of PP in the process of AD, we have evaluated the cross-sectional and longitudinal associations of PP with AD biomarkers, brain structure and cognition and have assessed the effect of PP on AD risk in a large sample (n= 1,375) from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Multiple linear regression and mixed-model regression were employed in cross-sectional and longitudinal analyses respectively. Clinical disease progression was assessed using Cox proportional hazards models. High PP was associated with lower β-amyloid 42 (Aβ42) (P= .015), and higher total tau (T-tau) (P= .011), phosphorylated tau (P-tau) (P= .003), T-tau/Aβ42 (P= .004) and P-tau/Aβ42 (P = .001), as well as heavier cortical amyloid-beta burden (P= .011). Longitudinally, baseline high PP was significantly associated with hippocampal atrophy (P= .039), entorhinal atrophy (P= .031) and worse memory performance (P= .058). Baseline high PP showed more rapid progression than those with normal PP (P <.001). These results suggest PP elevation could increase AD risk, which may be driven by amyloid plaques and subclinical neurodegeneration.

[1]  G. Baumbach Effects of increased pulse pressure on cerebral arterioles. , 1996, Hypertension.

[2]  A. Hofman,et al.  Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study , 1997, The Lancet.

[3]  W. Markesbery,et al.  Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS☆ , 2000, Neurobiology of Aging.

[4]  B. Winblad,et al.  Pulse Pressure and Risk of Alzheimer Disease in Persons Aged 75 Years and Older: A Community-Based, Longitudinal Study , 2003, Stroke.

[5]  C. Jack,et al.  Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD , 2004, Neurology.

[6]  C. Jack,et al.  Ways toward an early diagnosis in Alzheimer’s disease: The Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2005, Alzheimer's & Dementia.

[7]  A. Hofman,et al.  Atherosclerosis and risk for dementia , 2007, Annals of neurology.

[8]  G. Mitchell Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage. , 2008, Journal of applied physiology.

[9]  R. Carare,et al.  Lymphatic drainage of the brain and the pathophysiology of neurological disease , 2008, Acta Neuropathologica.

[10]  R. Carare,et al.  Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. , 2008, Brain pathology.

[11]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[12]  R. Weller,et al.  Microvasculature changes and cerebral amyloid angiopathy in Alzheimer’s disease and their potential impact on therapy , 2009, Acta Neuropathologica.

[13]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[14]  J. Schneider,et al.  High Blood Pressure and Microinfarcts: A Link Between Vascular Risk Factors, Dementia, and Clinical Alzheimer's Disease , 2009, Journal of the American Geriatrics Society.

[15]  R. Deane,et al.  SRF and myocardin regulate LRP-mediated amyloid-β clearance in brain vascular cells , 2009, Nature Cell Biology.

[16]  Jeffrey A. Fessler,et al.  Reducing between scanner differences in multi-center PET studies , 2009, NeuroImage.

[17]  B. Långström,et al.  The use of PET in Alzheimer disease , 2010, Nature Reviews Neurology.

[18]  Mark E. Schmidt,et al.  The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans , 2010, Alzheimer's & Dementia.

[19]  Nick C Fox,et al.  The clinical use of structural MRI in Alzheimer disease , 2010, Nature Reviews Neurology.

[20]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[21]  B. Zlokovic Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders , 2011, Nature Reviews Neuroscience.

[22]  V. Gudnason,et al.  Arterial stiffness, pressure and flow pulsatility and brain structure and function: the Age, Gene/Environment Susceptibility--Reykjavik study. , 2011, Brain : a journal of neurology.

[23]  C. Jack,et al.  An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease , 2012, Annals of neurology.

[24]  Philip S. Insel,et al.  Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2012, Brain Imaging and Behavior.

[25]  A. Fleisher,et al.  Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons , 2012, Neurobiology of Aging.

[26]  Philip S. Insel,et al.  A composite score for executive functioning, validated in Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment , 2012, Brain Imaging and Behavior.

[27]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[28]  L. Kuller,et al.  Pulse wave velocity is associated with β-amyloid deposition in the brains of very elderly adults , 2013, Neurology.

[29]  Mark E. Schmidt,et al.  The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception , 2012, Alzheimer's & Dementia.

[30]  C. Annweiler,et al.  Blood pressure levels and brain volume reduction: a systematic review and meta-analysis , 2013, Journal of hypertension.

[31]  Jeroen J. Bax,et al.  2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Blood pressure.

[32]  D. Levy,et al.  Relations of arterial stiffness and endothelial function to brain aging in the community , 2013, Neurology.

[33]  D. Salmon,et al.  Pulse pressure is associated with Alzheimer biomarkers in cognitively normal older adults , 2013, Neurology.

[34]  Owen Carmichael,et al.  Standardization of analysis sets for reporting results from ADNI MRI data , 2013, Alzheimer's & Dementia.

[35]  K. Blennow,et al.  Blood pressure decrease correlates with tau pathology and memory decline in hypertensive elderly , 2014, Neurobiology of Aging.

[36]  D. Drachman The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer's disease , 2014, Alzheimer's & Dementia.

[37]  D. Knopman β-Amyloidosis and neurodegeneration in Alzheimer disease , 2014, Neurology.

[38]  I. Wakabayashi Associations of blood lipid-related indices with blood pressure and pulse pressure in middle-aged men. , 2015, Metabolic syndrome and related disorders.

[39]  M. Carrillo,et al.  Revolutionizing Alzheimer's disease and clinical trials through biomarkers , 2015, Alzheimer's & dementia.

[40]  V. Srikanth,et al.  Type 2 diabetes mellitus and biomarkers of neurodegeneration , 2015, Neurology.

[41]  D. Salmon,et al.  Pulse pressure in relation to tau-mediated neurodegeneration, cerebral amyloidosis, and progression to dementia in very old adults. , 2015, JAMA neurology.

[42]  Timothy J. Hohman,et al.  The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease. , 2015, JAMA neurology.

[43]  Alexander Rauscher,et al.  Prevalence of Brain Microbleeds in Alzheimer Disease: A Systematic Review and Meta-Analysis on the Influence of Neuroimaging Techniques , 2016, American Journal of Neuroradiology.

[44]  P. Wolf,et al.  Pulse Pressure Is Associated With Early Brain Atrophy and Cognitive Decline: Modifying Effects of APOE-&egr;4 , 2016, Alzheimer disease and associated disorders.

[45]  M. Ihara,et al.  Interaction between cerebrovascular disease and Alzheimer pathology , 2016, Current opinion in psychiatry.

[46]  L. Wahlund,et al.  Cerebral microbleeds topography and cerebrospinal fluid biomarkers in cognitive impairment , 2017, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[47]  A. Rahmim,et al.  Association Between Midlife Vascular Risk Factors and Estimated Brain Amyloid Deposition , 2017, JAMA.

[48]  Sheree M. Johnson,et al.  Associations of Pulse and Blood Pressure with Hippocampal Volume by APOE and Cognitive Phenotype: The Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2018, Dementia and Geriatric Cognitive Disorders.

[49]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[50]  Yonas Akalu,et al.  Hypertension and Its Associated Factors Among Type 2 Diabetes Mellitus Patients at Debre Tabor General Hospital, Northwest Ethiopia , 2020, Diabetes, metabolic syndrome and obesity : targets and therapy.

[51]  H. Mak,et al.  Impaired cerebral blood flow in type 2 diabetes mellitus – A comparative study with subjective cognitive decline, vascular dementia and Alzheimer’s disease subjects , 2020, NeuroImage: Clinical.